<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63965">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107937</url>
  </required_header>
  <id_info>
    <org_study_id>SOV01</org_study_id>
    <secondary_id>2013-001322-26</secondary_id>
    <nct_id>NCT02107937</nct_id>
  </id_info>
  <brief_title>Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma</brief_title>
  <official_title>A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <authority>European Union: European Medicines Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/OvCa  added to Standard of Care
      chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in
      prolongation of progression free survival (PFS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall progression free survival (PFS)</measure>
    <time_frame>104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission after first line chemotherapy at 6 months</measure>
    <time_frame>0,10, 18, 30, 42 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission after first line chemotherapy at 12 months</measure>
    <time_frame>0,10, 18, 30, 42, 54, 68, 80, 92, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological progression free interval</measure>
    <time_frame>0,10, 18, 30, 42, 54, 68, 80, 92, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Response</measure>
    <time_frame>0, 6, 9, 12, 15, 18, 24, 30, 36, 42, 48, 54, 60 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring 2nd line chemotherapy</measure>
    <time_frame>0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50 percent survival</measure>
    <time_frame>0, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 21, 24, 27, 30, 36, 42, 48, 54, 60, 64, 68, 74, 80, 86, 92, 98, 104 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/OvCa with Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCVAC/OvCa in parallel with chemotherapy (Standard of Care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCVAC/OvCa sequentially chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DCVAC/OvCa sequentially after chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standart of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa with Standard of Care</intervention_name>
    <description>DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel</description>
    <arm_group_label>DCVAC/OvCa with Standard of Care</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa sequentially chemotherapy</intervention_name>
    <description>DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel</description>
    <arm_group_label>DCVAC/OvCa sequentially chemotherapy</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy</description>
    <arm_group_label>Standart of Care</arm_group_label>
    <other_name>Carboplatin</other_name>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged ≥18 years

          -  Patients with newly diagnosed, histologically confirmed, International Federation of
             Gynecology and Obstetrics (FIGO) stage III epithelial ovarian, primary peritoneal or
             fallopian tube carcinoma (serous, endometrioid or mucinous) who have undergone
             initial surgery up to 3 weeks before randomization and are selected to receive first
             line Standard of Care chemotherapy (optional prolongation to 6 weeks after surgery)

          -  Optimally debulked (zero residuum) or maximal residuum &lt;1cm

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0,1,2

        Exclusion Criteria:

          -  FIGO I,II,IV epithelial ovarian cancer

          -  FIGO III clear cells epithelial ovarian cancer

          -  Non-epithelial ovarian cancer (OvCa), borderline tumors (tumors of low malignant
             potential)

          -  Post-surgery residual disease with lesion(s) &gt;1cm

          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example
             chemotherapy, monoclonal antibody therapy (bevacizumab), tyrosine kinase inhibitor
             therapy, vascular endothelial growth factor (VEGF) therapy or hormonal therapy]

          -  Previous or concurrent radiotherapy to the abdomen and pelvis

          -  Malignancy other than epithelial ovarian cancer, except those that have been in
             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the
             cervix or non-melanoma skin carcinomas

          -  Patient co-morbidities:Human immunodeficiency virus (HIV) positive, human
             T-lymphotropic virus (HTLV) positive, Active hepatitis B (HBV), active hepatitis C
             (HCV), active syphilis

          -  Evidence of active bacterial, viral or fungal infection requiring systemic treatment

          -  Clinically significant cardiovascular disease including:

        Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia
        requiring medication Uncontrolled hypertension Myocardial infarction or ventricular
        arrhythmia or stroke within a 6 month period before inclusion, ejection fraction (EF) &lt; 40
        percent or serious cardiac conduction system disorders, if a pacemaker is not present
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Richard Kapsa</last_name>
    <phone>: (+420) 2241 74448</phone>
    <email>kapsa@sotio.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>České Budějovice</city>
        <zip>370 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <zip>01465</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serous</keyword>
  <keyword>endometrioid</keyword>
  <keyword>mucinous</keyword>
  <keyword>epithelial ovarian cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
